ABSTRACT Introduction Acquired hemophilia A (AHA) is a rare hemorrhagic autoimmune
disorder characterized by autoantibodies against coagulation factor VIII (FVIII). In …

Acquired hemophilia A (AHA) is a rare but serious bleeding disorder. Randomized
controlled trial (RCT) comparing the efficacy of immunosuppression therapy for AHA lacks …

Acquired hemophilia A (AHA) is a bleeding disorder characterized by the immunological
inhibition of factor VIII (FVIII) of the hemostatic pathway leading to hemorrhagic events …

Background One-third of patients with severe hemophilia A develop neutralizing antibodies
to the factor VIII (FVIII) protein in response to intravenous replacement therapy. Patients may …

Methods: We conducted a retrospective analysis of the medical records of a 68-year-old
male patient who presented with adalimumabinduced AHA. Results: The patient received …

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder which can be life-
threatening. AHA is due to autoantibodies against coagulation factor VIII. Disease onset may …

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by
autoantibodies against FVIII. Severe AHA is life‐threatening. Currently, licensed hemostatic …

Abstract Introduction Acquired hemophilia A (AHA) is a rare bleeding disorder with
destruction of factor VIII by autoantibodies. Comprehensive data for Chinese patients are …

Acquired haemophilia A (AHA) is a rare haemorrhagic disease characterised by new‐onset
haemorrhagic symptoms associated with a dramatic decrease in factor VIII levels and an anti …

Abstract Introduction Acquired hemophilia A (AHA) is a rare hemorrhagic disorder caused by
factor VIII (FVIII) inhibitors. The diagnosis and management of AHA remains challenging …